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Abstract 
Background: Some observational studies have suggested that higher prenatal Vitamin D 
intake may be associated with improved health outcomes in childhood. However there have 
been mixed results in this area with some negative studies, especially for effects on atopic 
and respiratory outcomes. We examined the effect of prenatal Vitamin D on healthcare 
utilisation in the first three years of life. 
Methods: In an ethnically stratified randomised controlled trial conducted at St Mary’s 
Hospital London, 180 women at 27 weeks gestation were allocated to no Vitamin D, 800 IU 
ergocalciferol daily until delivery, or a single oral bolus of 200,000 IU cholecalciferol. 
Participants were randomised in blocks of 15 using computer-generated numbers and 
investigators were blinded to group assignment. Supplementation increased maternal and 
cord blood 25(OH) vitamin D concentrations, but levels remained lower than current 
recommendations. Primary health economic outcome was overall cost of unscheduled 
healthcare utilisation in the first three years of life as documented in the child’s electronic 
health record. Secondary outcomes included cost attributable to: primary and secondary 
healthcare visits, respiratory and atopic complaints, cost in years 1, 2 and 3 of life and cost 
and frequency of prescribed medication. All costs were calculated as pounds sterling. 
Differences between groups were analysed using unpaired t-test or Mann-Whitney U test, 
and analysis of variance for adjusted analyses. 
Results: We assessed 99/180 (55%) complete electronic health records, control (n=31), 
daily (n=36) and bolus (n=32). We found no difference in total healthcare utilisation costs 
between the control and daily (mean difference in costs in pounds sterling 1.02, 95%CI -
1.60, 1.65; adjusted 1.07, 95%CI -1.62, 1.86) or control and bolus groups (mean difference -
1.58, 95%CI -2.63, 1.06; adjusted –1.40, 95%CI -2.45, 1.24).  There were no adverse effects 
of supplementation reported during the trial. 
Conclusions: We found no evidence that prenatal vitamin D supplementation from 27 
weeks gestation to delivery, at doses which failed to completely correct maternal vitamin D 
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deficiency, influence overall healthcare utilisation in children in the first 3 years.
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Introduction  
Hypovitaminosis D is an increasing problem in many regions, where sedentary, indoor 
lifestyles are thought to be a major contributing factor [1].  There is mixed observational 
evidence with regards to the effect of pre-natal 25(OH) vitamin D status on child health 
outcomes.  Several studies have linked low vitamin D status to a number of resource 
intensive childhood health problems including allergy and infection [2-7], in addition to the 
well-established effects on bone metabolism. However, these links remain controversial with 
other studies reporting no association [8-11]. Allergy alone accounts for 6% of primary care 
consultations and 70,000 hospital admissions a year in the UK [12] and the average pre-
school UK child contracts 6-8 upper respiratory tract infections (URTIs) annually. Vitamin D 
supplementation during critical periods of immune development may represent a safe [13] 
and relatively inexpensive public health intervention to reduce this burden. Thus far there 
has been a lack of randomised controlled trial evidence to definitively confirm or refute the 
relationship between prenatal vitamin D and childhood health outcomes found in 
observational studies. Data published in 2013 from this trial, looking primarily at respiratory 
outcomes, found no difference between treatment and control arms with regards to a 
primary outcome of wheeze [14].  
 
In the United Kingdom, all children registered with a primary care practice have an electronic 
health record (e-HR). This is a contemporaneous record of all health care utilisation from 
that practice. Use of primary care out of hours services (OOH) or secondary healthcare is 
also recorded, and the e-HR follows the child if they move so that the e-HR forms a 
complete record of a child’s healthcare utilisation from birth. Determinants of a child’s overall 
healthcare utilisation are their underlying health status [15-19], parent mental health and 
family functioning [20-22], and socioeconomic predictors (age and ethnicity of the child, 
family income, area of residence, parental educational attainment and social class) [15, 19, 
23-25], although not all studies have found an effect of social class [16, 17].   
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We hypothesized that prenatal vitamin D supplementation during pregnancy would reduce a 
child’s healthcare utilisation during the first three years of life through improved health 
status, by using the e-HR to quantify our outcome total healthcare utilisation.   
Methods 
Study Setting and Subjects 
This was a follow up study of the offspring of 180 women who took part in an ethnically 
stratified, parallel group, randomised controlled trial of vitamin D supplementation in 
pregnancy at St Mary’s Hospital London, a university-affiliated hospital antenatal clinic, 
between April and November 2007.  Eligible participants were women presenting at 27 
weeks gestation for routine glucose challenge test from the following ethnic groups: Indian 
Asian, Middle Eastern, Afro-Caribbean and Caucasian. Participants were excluded if there 
were severe congenital or developmental abnormalities likely to significantly affect 
respiratory health or lung function e.g. thoracic dystrophy. There were no withdrawal criteria 
for this study. 
Ethics Statement 
St Mary’s Hospital Research Ethics Committee approved the follow-up study (10/H0712/13). 
Consent was obtained in person or over the telephone, in which case verbal consent was 
taken and documented by two separate members of the research team. The ethics 
committee approved verbal consenting in this manner. The confidentiality of all participants 
has been preserved under the Data Protection Act.  
Study Design 
Women were randomised at 27 weeks gestation to no treatment (control), 800 IU 
ergocalciferol until delivery (daily) or a single oral dose of 200,000 IU cholecalciferol (bolus). 
The randomisation sequence was generated by an independent person using computer 
generated random number lists in blocks of 15, stratified by ethnicity in a 1:1:1:1 ratio. The 
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researcher gave participants a study number on entry to the trial, and treatment was 
allocated from the hospital pharmacy using the randomization list. Women were given 
instructions to swallow the tablets whole and to avoid other multivitamin supplements 
containing vitamin D.  This trial was conducted before national guidance on routinely 
providing advice on vitamin D intake during pregnancy was introduced in March 2008 [26].  
No adverse effects were reported. Vitamin D deficiency was defined as 25(OH)D <25nmol/L, 
and insufficiency as 25(OH)D ≥25 but <50nmol/L [27]. We obtained e-HR for those who 
consented. For analysis, two assessors independently examined the first three e-HRs (84 
consultations). The kappa score for their assessment of total healthcare utilisation costs was 
0.972, showing excellent agreement.  The remaining records were all analysed by a single 
assessor. All assessors were blinded to the randomisation of participants, with the use of 
separate trial numbers, until the evaluation of all records was complete. A complete record 
was defined as having data for at least 11 months out of 12 for each year, and including all 
three years since birth. The flow of participants is shown in Fig 1.  
Primary and secondary outcomes 
The primary outcome of the trial was 25(OH) vitamin D level at birth, and has been reported 
elsewhere [28]. The primary outcome for the follow-up study was wheeze in the first 3 years 
of life – this together with other clinical, physiological and immune outcomes has already 
been reported [14]. The primary outcome of this health economic analysis was the total cost 
of unscheduled NHS healthcare utilisation across primary and secondary care recorded in 
the e-HR from birth until the child’s third birthday, including both visit costs and prescription 
costs. Scheduled care such as routine developmental checks and vaccinations was not 
included.  Secondary outcomes were as follows: total costs for the first, second and third 
year of life separately; total primary care visit costs, total secondary care visit costs, 
respiratory costs i.e. healthcare utilisation attributed to wheeze, cough, upper respiratory 
tract infection, lower respiratory tract infection and bronchiolitis; food allergy costs, eczema 
costs; prescription costs attributable to wheezing and eczema (separately). 
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Primary healthcare consultations were classified according to the professional providing the 
service (general practitioner, out of hours service or nurse) and location (surgery, telephone 
or home visit).  Entries without details were classed as ‘primary care; unknown’.  Secondary 
healthcare utilization was classified as new outpatient appointment, follow-up outpatient 
appointment, accident and emergency attendance, ward admission or intensive care unit 
admission.  For admissions, the number of nights in hospital was recorded. Entries 
regarding administrative tasks were not included.  Coding definitions are shown in Table 1. 
Table 1. Diagnostic codes for electronic health records 
Outcome Definition.  Any record of the following in the e-HR 
Wheeze Wheeze or asthma excluding wheeze in the context of bronchiolitis 
Cough   Cough excluding cough in the context of URTI or LRTI 
URTI URTI, pharyngitis, rhinorrhoea, laryngitis, tonsillitis, sinusitis or otitis 
media. Or at least two of fever, sore throat, earache, sticky eye or 
cough 
LRTI LRTI, chest infection, respiratory infection, bronchitis or pneumonia. Or 
cough with a record of signs of infection such as crackles on 
auscultation 
Bronchiolitis Bronchiolitis 
Food allergy Doctor diagnosed food allergy 
Eczema Eczema or eczematous skin 
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection). 
Visit costs 
Costs were calculated according to standard NHS tariffs for 2009 in pounds sterling, that 
included training and, where applicable, travel costs and direct care staff costs. All costs are 
reported in pounds sterling, either as raw or natural log transformed figures. As no unit cost 
was given for telephone calls with a practice nurse, this was estimated as follows: a 
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telephone consultation with an advanced nurse is six minutes long on average. When 
applied to the hourly rate for client consultation with a GP practice nurse (£34) this gives an 
average cost of £3.40 per call.  A factor of 1.44 was applied to in hours GP utilization to give 
the estimated out of hours cost.  This is based on the mean cost per hour for out of hours 
GP services being £82.03 (Inflation adjusted average), [29] which is 44% more than the 
mean cost per hour for in hours GP services of £57.03 [30]. For secondary care new and 
follow-up outpatient attendances, a weighted mean of the cost of all types of paediatric 
referrals for consultant led outpatient care was taken, giving an overall mean of £198.60 for 
a first appointment and £155.36 for a follow-up appointment.  Similar methods were used for 
accident and emergency attendances, such that the weighted mean for an A&E attendance 
leading to admission was £129.11, and an A&E attendance without admission £94.93. This 
cost excludes the use of minor injury services and walk-in centres. The details of NHS 
costing codes used in analysis can be found in Table 2 [31]. 
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Table 2. Costs used for calculation of healthcare utilization, and their source 
Type of Utilization Unit 
Cost 
(GBP) 
Source 
Primary Care 
Nurse In Surgery 11 Units costs by Curtis 2009 [30] 
Nurse Telephone Consultation 3.4 Units costs by Curtis 2009 [30] 
Nurse Home Visit 20 Units costs by Curtis 2009 [30] 
GP In Surgery  35 Units costs by Curtis 2009 [30] 
GP Telephone Consultation 21 Units costs by Curtis 2009 [30] 
GP Home Visit 117 Units costs by Curtis 2009 [30] 
OOH In Surgery 50.4 Units costs by Curtis 2009 [30]  Unit costs by 
Curtis 2010 [32], NAO report OOH Care [33] 
OOH Telephone Consultation 30.24 Units costs by Curtis 2009 [30] Unit costs by 
Curtis 2010[32] NAO report OOH Care[33] 
OOH Home Visit 168.48 Units costs by Curtis 2009 [30]Unit costs by 
Curtis 2010 [32], NAO report OOH Care [33] 
Secondary Care 
First Attendance to Consultant Led OP 198.6 Appendix NSRC4 NHS Trust [31] 
Follow-up Attendance to Consultant Led 
OP 
155.36 Appendix NSRC4 NHS Trust [31] 
A &E Attendance Leading to Admission   129.11 Appendix NSRC4 NHS Trust [31] 
A&E Attendance Not Leading to 
Admission 
94.93 Appendix NSRC4 NHS Trust [31] 
Inpatient Stays 
Kidney or Urinary Tract Infections with 
length of stay less 1 day or less 
392 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: LA04G [31] 
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Penile Conditions and Minor 
Procedures 18 years and under 
1307 Appendix NSRC4 NHS Trust Elective 
Inpatient Code:LB32C [31] 
Major Neonatal Diagnoses 2075 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Long Stay) Code: PB01Z [31] 
Major Congenital Conditions under 1 
year without CC 
537 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: PA59D [31] 
Major Congenital Conditions 1 year 
and over without CC 
535 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: PA59F [31]  
Acute Febrile illness length of stay 4 
days or less without CC 
378 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: WA04U [31] 
Viral Infections with length of stay 2 
day or more 
922 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: PA19B [31] 
Fever unspecified without CC 487 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: PA20B [31] 
Other Viral illness without CC 368 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: WA06Y [31]  
Feeding Difficulties and Vomiting 
without CC 
455 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: PA28B [31] 
Infectious and Non-Infectious 
Gastroenteritis without CC 
459 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: PA21B [31] 
Intermediate Mouth or Throat 
Procedures 18 years and under with 
CC 
1799 Appendix NSRC4 NHS Trust Elective 
Inpatient Code: CZ02S [31] 
Other Respiratory Diagnoses without 
CC 
342 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: DZ19C [31] 
Acute Bronchiolitis without CC 489 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: PA15B [31] 
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Acute Bronchiolitis with CC 573 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code:PA15A [31] 
Lower Respiratory Tract Disorders 
without Acute Bronchiolitis with length 
of stay 1 day or more without CC 
544 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: PA14D [31] 
Minor Skin disorders category 2 without 
CC 
396 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: JD05C [31]  
Non-Malignant General Abdominal 
Disorders with length of stay 0 days 
410 Appendix NSRC4 NHS Trust Non-Elective 
Inpatient (Short Stay) Code: FZ47C [31] 
GP- general practitioner, OOH – out of hours, OP- outpatient, CC- critical care. 
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Prescription costs 
Prescription costs were calculated from the online version of the British National Formulary 
for Children 2011 [34]. These reflect the cost of drugs issued and not the cost of 
administration associated with delivery to patients.  The price of the pharmaceutical brand 
specified in the record was taken. If no brand was specified the cheapest form of that 
medication with the same mode of delivery was used. Where costs were itemized as a net 
price per measured unit of drug (for example per 100ml), the price was applied proportional 
to the amount prescribed. Where the drug was priced per set volume (for example per tube 
in the case of creams) then the number of tubes required to cover the volume prescribed 
was calculated. The summation of the medication costs in each record was then subjected 
to deflation calculations using inflation indices [32]. As no inflation indices for 2010/11 were 
available at the time of calculation, the indices to deflate 2010 to 2009 were used twice, 
thereby assuming a similar rate of inflation across that time. Deflating prices to 2008/09 
brought them to the same base year as the healthcare utilization costs.  The price of Anusol 
cream and Dentinox oral solution were not available within the BNFC 2010 and were priced 
from Boots pharmacy; each of these were prescribed once.  Whether or not a child was 
prescribed drugs relevant to eczema (emollient creams and bath oils, topical corticosteroids 
with or without antibiotics or antiseptic and calcineurin inhibitors), asthma (inhaled 
corticosteroids, B2 agonists, leukotriene inhibitors and delivery devices) or food allergy 
(adrenaline autoinjectors and antihistamines) was separately recorded. 
Statistical analyses 
A database was assembled using Microsoft Excel. Data were explored using histograms and 
the following became normally distributed after natural log transformation: total healthcare 
utilization, total visit costs, total prescription costs, total primary care costs, total year 1 costs 
and overall respiratory costs. Levels of 25(OH)D at baseline in the mother, in cord blood and 
at age three years in the child were all normally distributed after natural log transformation.  
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0.1 was added to all zero values to allow natural log transformation.  The following data 
remained non-normally distributed despite natural log transformation:  total secondary care 
costs, year 2 and 3 costs, respiratory costs, food allergy costs, eczema costs and 
prescription costs for eczema and wheezing medications.  
Primary analysis evaluated control versus daily supplement and control versus bolus 
supplement. Secondary analysis included bolus and daily vitamin D groups combined 
(combined vitamin D) compared with the control group and the relationship between 
25(OH)D levels measured in cord blood at delivery and in the child at age three years.  
Differences between groups were analysed using the independent student t-test or Mann-
Whitney U test according to whether the data were normally distributed or not. Where 
analysis was performed on log transformed data, the results have undergone exponentiation 
for presentation in the tables.  Analysis of variance was performed on normally distributed 
data using potential covariates that have been associated with healthcare utilisation in the 
literature including mother’s age, mother’s age on leaving full time education, gestational 
age, ethnicity, parity, maternal body mass index (BMI), smoking during pregnancy and mode 
of delivery [24]. Logistic regression was used to calculate adjusted odds ratios for 
dichotomised data regarding prescriptions for wheeze and eczema related drugs. All 
analyses were performed using SPSS version 19.0 (IBM, Chicago USA).  A value of p<0.05 
was considered statistically significant. 
Formal Bonferroni correction for multiple analyses was not performed, but statistical 
significance was interpreted cautiously where multiple analyses had been made [35].
Results 
Of the 180 offspring from the original trial, we successfully obtained 130 e-HRs from their GP’s 
between January and May 2011. 31 had incomplete data and could not be used, leaving 99/180 
(55%) infants with complete e-HR data for analysis.  An additional 12 records were incomplete but 
had at least one year’s health data for analysis. Incomplete records were due to inadequate GP 
summaries or where the patient had moved GP practice over the last three years and we were unable 
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to obtain the old or new records. Only records with complete data were used for primary analysis.  
Participant flow through the study can be found in Fig. 1. Table 3 shows the characteristics of children 
for whom complete e-HR data was obtained and analysed and those who were not analysed (either 
incomplete or not received). There were minor differences between groups with a slightly higher 
proportion of Middle Eastern children with incomplete records and a slightly higher proportion of Black 
children for whom no record was received. However, the groups remain relatively similar in most 
respects. The characteristics of children with complete records in each randomization group are 
shown in Table 4. 
Fig 1. CONSORT flow diagram. 
Table 3. Characteristics of children with complete e-HR data, incomplete e-HR data and for 
whom no e-HR data were received. 
 Complete(n=99) Incomplete(n=12) Not Received(n=69) 
Male sex, n (%) 52/99 (53) 7/12 (58) 34/69 (49) 
Gestational age, weeks 39.6 (1.57) 40.5 (1.27) 39.6 (1.27) 
Delivery by caesarean section, n (%)  30/99 (30) 4/12 (33) 23/69  (33) 
Cord blood 25(OH) Vitamin D 
available, n (%) 
79/99 (80) 7/12 (58) 55/69 (80) 
Mean cord blood 25(OH) Vit D 
(nmol/L) 
26.9 (13.6) 30.6 (19.1) 24.3 (11.0) 
Maternal Ethnicity, n (%) Asian 25/99 (25) 3/12 (25) 17/69 (25) 
 
Middle 
Eastern 25/99 (25) 5/12 (42) 15/69 (22) 
 Black 21/99 (21) 2/12 (17) 21/69 (30) 
 Caucasian 28/99 (28) 2/12 (17) 16/69 (23) 
Maternal age at booking, years 32 (6.45) 30 (5.47) 30 (6.02) 
Maternal smoking in pregnancy, n (%) 13/99 (13) 0/12 (0) 6/69 (9) 
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Multiparous, n (%) 65/99 (66) 5/12 (42) 31/69 (45) 
Maternal BMI at booking 27 (6.07) 26 (5.51) 25 (4.99) 
Maternal 25(OH) Vit D at delivery 
available n(%) 
86/99 (87) 10/12 (83) 62/69 (90) 
Maternal 25(OH) Vit D at delivery  42.65 (22.2) 44.0 (22.3) 37.9 (18.0) 
Continuous data are presented as mean (standard deviation).  BMI = body mass index. 
 
 
 
Table 4. Characteristics of children with complete e-HR data 
 Control (n=31) Daily (n=36) Bolus (n=32) 
Male sex, n (%) 15/31 (48) 22/36 (61) 17/32 (53) 
Gestational age, months 39.92 (1.28) 39.40 (1.53) 39.72 (1.66) 
Delivery by caesarean section, n (%)  10/31 (32) 10/36 (28) 10/32 (31) 
Cord blood 25(OH) Vitamin D available, 
n (%) 
24/31 (77) 29/36 (81) 26/32 (81) 
Mean cord blood 25(OH) Vit D (nmol/L) 18.8 (9.4) 34.1 (16.3) 26.4(8.31) 
Maternal Ethnicity, n (%) Asian 6/31 (19) 10/36 (28) 9/32 (28) 
 
Middle 
Eastern 11/31 (35) 8/36 (22) 6/32 (19) 
 Black 5/31 (16) 8/36 (22) 8/32 (25) 
 Caucasian 9/31 (29) 10/36 (28) 9/32 (28) 
Maternal age at booking, years 30 (7) 32 (6) 32 (6) 
Maternal highest education, years 20 (3) 20 (4) 20 (3) 
Family history of atopy, n (%) 13/29 (45) 23/35 (63) 15/31 (48) 
Maternal smoking in pregnancy, n (%) 5/31 (16) 5/36 (14) 3/31 (10) 
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Number children in household 2 (1) 2 (1) 3 (1) 
Multiparous, n (%) 19/31 (61) 25/36 (69) 21/32 (66) 
Maternal BMI > 30 at booking, n (%) 9/31 (29) 4/36 (11) 4/32 (12.5) 
Maternal 25(OH) Vit D at delivery 
available n(%) 
26/31(83) 33/36 (92) 27/32 (84) 
Maternal 25(OH) Vit D at delivery 33.0 (17.6) 55.3(27.0) 36.5(9.5) 
Continuous and ordinal data are presented as mean (standard deviation).  BMI = body mass index.
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Effect of prenatal vitamin D supplementation on healthcare utilisation  
There was no significant difference in the primary outcome measure, total unscheduled healthcare utilisation, between treatment groups 
(Fig.2). Mean difference between control and daily vitamin D supplementation in Ln transformed total costs was - 0.02 (95%CI -0.47, 0.50); 
adjusted mean difference 0.07 (95%CI -0.48, 0.62). For bolus vitamin D supplementation versus controls the mean difference was -0.46 
(95%CI-0.97, 0.06); adjusted mean difference -0.34 (95%CI -0.90, 0.22).   
We also found no significant difference in secondary outcomes including total prescription costs, total visit costs, costs in years 1, 2 and 3 and 
costs specific to respiratory or allergic disorders, between offspring in the daily treatment group compared to controls (Table 5).  There was 
weak evidence that secondary care health utilisation costs (p=0.048) and year 3 costs (p=0.045) were reduced in the bolus group (Table 6).  
When treatment groups were combined for analysis, no difference was found from controls (Table 7). 
Fig 2. Effect of prenatal vitamin D randomisation on total healthcare utilisation in the first three years of life. 
Horizontal bars represent medians and p values are for adjusted analyses. 
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Table 5. Healthcare utilisation in the first three years of life. Daily vitamin D versus control. 
 n Control* n Daily* Mean difference 
(95% CI) 
p n Adjusted** mean difference 
(95% CI) 
p 
Total cost† 31 1176.14 
(437.03, 
3165.29) 
36 1187.97 
(441.42, 
3197.10) 
1.02 (-1.60, 1.65)  0.95 53 1.07 (-1.62, 1.86)  0.81 
All Visits† 31 1130.03 
(419.90, 
3041.18) 
36 1118.79 
(407.48, 
3071.74) 
-1.01 (-1.65, 1.60)  0.95 53 1.02 (-1.70, 1.79)  0.93 
Prescription cost† 31 25.28 (4.06, 
157.60) 
36 35.52 (11.59, 
108.85) 
1.40 (-1.49, 2.94)  0.36 53 1.65 (-1.43, 3.90)  0.25 
Year 1 cost† 31 287.15 (38.09, 
2164.62) 
36 383.75 (86.49, 
1702.75) 
1.34 (-1.75, 3.16) 0.50 53 1.67 (-1.58, 4.39)  0.30 
Year 2 cost 31 247 (103, 607) 36 248 (123, 487) - 0.92 - - - 
Year 3 cost 31 239 (103, 552) 36 212 (96, 463) - 0.57 - - - 
Primary care cost† 31 387.61 (145.47, 
1032.77) 
36 450.39 (242.26, 
837.15) 
1.15 (-1.28, 1.72)  0.47 53 1.34 (-1.16, 2.05) 0.20 
Secondary care cost 31 632 (206, 1853) 36 368 (155, 1502) - 0.42 - - - 
Wheeze cost 31 0 (0, 0) 36 0 (0, 0) - 0.71 - - - 
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Cough cost 31 0 (0, 36) 36 0 (0, 36) - 0.26 - - - 
URTI cost 31 180 (36, 324) 36 150 (54, 234) - 0.78 - - - 
LRTI cost 31 0 (0, 0) 36 0 (0, 0) - 0.75 - - - 
Bronchiolitis cost 31 0 (0, 0) 36 0 (0, 0) - 0.89 - - - 
Overall resp cost† 31 170.72 (27.39, 
1064.22) 
36 141.17 (27.11, 
735.10) 
-1.21 (-3.16, 2.14)  0.69 - - - 
Food allergy cost 31 0 (0, 0) 36 0 (0, 0) - 0.35 - - - 
Eczema cost 31 0 (0, 88) 36 0 (0, 36) - 0.62 - - - 
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).   
All costs are in pounds sterling. 
*Mean ± 95% CI or Median (IQR) 
**Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, 
Middle Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors. 
†Analysis performed on Ln data, results have undergone exponentiation for presentation in tables
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Table 6. Healthcare utilization in the first three years of life. Bolus vitamin D versus control. 
 n Control* n Bolus* Mean difference 
(95% CI) 
p n Adjusted** mean difference 
(95% CI) 
p 
Total cost† 31 1176.14 
(437.03, 
3165.29) 
31 742.48 (257.24, 
2413.08) 
-1.58 (-2.63, 1.06) 0.08 49 -1.40 (-2.45, 1.24)  0.23 
All visit costs† 31 1130.03 
(419.90, 
3041.18) 
32 706.27 (239.85, 
2079.74) 
1.60 (-2.69, 1.05) 0.08 49 -1.43 (-2.53, 1.23)  0.21 
All prescription cost† 31 25.28 (4.06, 
157.60) 
32 22.42 (4.85, 
103.54) 
1.12 (-2.61, 2.08)  0.79 49 1.23 (-1.95, 3.00)  0.63 
Year 1 cost† 31 287.15 (38.09, 
2164.62) 
32 223.63 (62.80, 
796.32) 
1.28 (-2.97, 1.82)  0.56 49 1.02 (-2.36, 2.46) 0.96 
Year 2 cost 31 247 (103, 607) 32 202 (101, 603) - 0.75 - - - 
Year 3 cost 31 239 (103, 552) 32 142 (36, 333) - 0.04 - - - 
Primary care cost† 31 387.61 (145.47, 
1032.77) 
32 383.75 (169.02, 
871.32) 
1.02 (-1.60, 1.55) 0.95 49 1.01 (-1.57, 1.60) 0.98 
Secondary care cost 31 632 (206, 1853) 32 313 (0, 848) - 0.04 - - - 
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Wheeze visit cost 31 0 (0, 0) 32 0 (0, 0) - 0.22 - - - 
Cough visit cost 31 0 (0, 36) 32 0 (0, 36) - 0.59 - - - 
URTI visit cost 31 180 (36, 324) 32 108 (72, 255) - 0.91 - - - 
LRTI visit cost 31 0 (0, 0) 32 0 (0, 36) - 0.31 - - - 
Bronchiolitis visit cost 31 0 (0, 0) 32 0 (0, 0) - 0.59 - - - 
Overall resp cost† 31 170.72 (27.39, 
1064.22) 
32 137.00 (15.96, 
1176.15) 
-1.25 (-3.42, 2.20) 0.66 - - - 
Food allergy cost 31 0 (0, 0) 32 0 (0, 0) - 1.00 - - - 
Eczema cost 31 0 (0, 88) 32 0 (0, 36) - 0.77 - - - 
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).   
All costs are in pounds sterling. 
*Mean ± 95% CI or Median (IQR) 
**Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, 
Middle Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors. 
†Analysis performed on Ln data, results have undergone exponentiation for presentation in the table
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Table 7. Healthcare utilization costs in the first three years of life. Combined vitamin D versus control. 
 n Control* n Combined* Mean difference p n Adjusted** mean difference p 
Total cost† 31 1176.14 
(437.03, 
3165.29) 
68 953.37 (333.62, 
2724.39) 
-1.23 (-1.92, 1.27) 0.36 84 -1.17 (-1.90, 1.39) 0.52 
All visit cost† 31 1130.03 
(419.90, 
3041.18) 
68 897.85 (311.06, 
2591.52) 
-1.27 (-1.95, 1.25) 0.31 84 -1.21 (-1.97, 1.35) 0.45 
All prescription cost† 31 25.28 (4.06, 
157.60) 
68 28.50 (7.32, 
111.05) 
1.14 (-1.70, 2.18) 0.70 84 1.34 (-1.49, 2.66) 0.41 
Year 1 total cost† 31 287.15 (38.09, 
2164.62) 
68 298.87 (74.44, 
1199.91) 
1.04 (-1.93, 2.08)  0.91 84 1.25 (-1.70, 2.63) 0.56 
Year 2 total cost 31 247 (103, 607) 68 244 (108, 558) - 0.81 - - - 
Year 3 total cost 31 239 (103, 552) 68 168 (60, 430) - 0.14 - - - 
Primary care visit cost† 31 387.61 (145.47, 
1032.77) 
68 415.72 (202.35, 
854.06) 
1.07 (-1.32, 1.52) 0.70 84 1.16 (-1.25, 1.67) 0.42 
Secondary care visit cost 31 632 (206, 1853) 68 316 (103, 1050) - 0.11 - - - 
Wheeze visit cost 31 0 (0,0) 68 0 (0, 0) - 0.37 - - - 
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Cough visit cost 31 0 (0, 36) 68 0 (0, 36) - 0.33 - - - 
URTI visit cost 31 180 (36, 324) 68 130 (72, 252) - 0.82 - - - 
LRTI visit cost 31 0 (0, 0) 68 0 (0, 24) - 0.68 - - - 
Bronchiolitis visit cost 31 0 (0, 0) 68 0 (0, 0) - 0.70 - - - 
Overall resp cost† 31 170.72 (27.39, 
1064.22) 
68 138.38 (347.23, 
1107.65) 
-1.23 (2.92, 1.93) 0.64 - - - 
Food allergy cost 31 0 (0, 0) 68 0 (0, 0) - 0.50 - - - 
Eczema cost 31 0 (0, 88) 68 0 (0, 36) - 0.90 - - - 
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).   
All costs are in pounds sterling. 
*Mean ± 95% CI  or Median (IQR) 
**Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, 
Middle Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors 
†Analysis performed on Ln data, results have undergone exponentiation for presentation in table
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Effect of prenatal vitamin D supplementation on need for prescription medications 
Prescribing data were also dichotomized according to whether any prescription was made in 
the first three years of life.  There was weak evidence that offspring of mothers who received 
bolus vitamin D were more likely to have been prescribed a wheezing medication (p=0.05), 
and that offspring of mothers who received daily vitamin D were more likely to have been 
prescribed an eczema medication (p=0.04) (Table 8).  We therefore evaluated the number of 
prescriptions for medicated skin creams or wheezing medications, to further explore the 
possible association with eczema and wheezing medications. Here we found no difference 
in the number of prescriptions issued for medicated skin creams (median 1.0 IQR 0.0, 2.0 
combined vitamin D versus 0.0 (0.0, 2.0) controls; p=0.27) or wheezing medications (median 
0.0 IQR 0.0, 1.0 combined vitamin D versus 0.0 (0.0, 0.0) controls; p=0.42). There were 
insufficient data to analyse bolus and daily vitamin D groups separately for this outcome.  
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Table 8. Any prescription for wheezing or eczema.  Daily, bolus and combined groups 
vs controls.  
 Control n 
(%) 
Treatment 
group, n 
(%) 
Unadjusted 
OR (95%CI) 
p n aOR1 (95% 
CI) 
p 
Wheezing medications 
Daily vs controls 4/31 
(12.9) 
8/36 
(22.2) 
1.93 (0.66, 
1.97) 
0.32 66 3.19 (0.57, 
17.77) 
0.19 
Bolus vs controls 4/31 
(12.9) 
11/32 
(34.4) 
3.54 (0.98, 
12.70) 
0.05 62 4.07 (0.98, 
16.84) 
0.05 
Combined vs 
controls 
4/31 
(12.9) 
19/68 
(27.9) 
2.62 (0.81, 
8.49) 
0.11 96 3.08 (0.85, 
11.24) 
0.09 
Eczema medications 
Daily vs controls 14/31 
(45.2) 
22/36 
(61.1) 
1.91 (0.72, 
5.06) 
0.19 66 3.60 (1.05, 
12.34) 
0.04 
Bolus vs controls 14/31 
(45.2) 
15/32 
(46.9) 
1.07 (0.40, 
2.89) 
0.89 62 2.13 (0.60, 
7.53) 
0.24 
Combined vs 
controls 
14/31 
(45.2) 
37/68 
(54.4) 
1.45 (0.62, 
3.40) 
0.39 96 2.22 (0.82, 
6.02) 
0.12 
aOR (Adjusted odds ratio).  1Adjusted for mother’s age, mother’s age on leaving education 
and gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle 
Eastern, Black), parity, BMI>30, smoking during pregnancy and mode of delivery (vaginal, 
instrumental or caesarean) as potential cofactors. 
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Association between prenatal or postnatal vitamin D level and healthcare utilisation 
Of the 99 offspring with complete e-HR data, cord levels of 25(OH)D were available for 79, 
and 25(OH)D levels at age three years for 65. There was no correlation between either of 
these measures and any healthcare utilisation outcome (Fig.3 A-B; Table 9; Table 10). To 
further investigate the weak evidence for a link between cord blood 25(OH) vitamin D 
concentration and eczema cost (Table 9), we analysed whether there was a relationship 
between cord 25(OH) vitamin D level and prescription of a medicated cream (aOR 2.52, 
p=0.10, 95% CI 0.85-7.47) and whether cord 25(OH) vitamin D was associated with the 
number of eczema medications prescribed (r=0.07, p=0.91, 95% CI -0.72 -7.80). No 
evidence for an association was found. 
Fig 3. Cord and childhood 25(OH)D levels and total healthcare utilisation in the first three 
years of life.Adjusted correlation (Beta coefficient, β) between 25(OH) vitamin D levels 
measured at A) Birth and total healthcare utilization at age three years B) Age three years 
and total health care utilization by age three years.
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Table 9. Cord 25(OH)D levels and healthcare utilisation in the first three years of life.   
Outcome n p β or  n Adjusted
1 β p 
Ln total healthcare 79 0.58 -0.06 76 -0.02 0.89 
Ln all visit cost 79 0.54 -0.07 76 -0.01 0.93 
Ln all prescription 
cost 
79 0.78 -0.03 76 0.12 0.36 
Ln year 1 cost 79 0.57 -0.07 76 0.01 0.94 
Year 2 cost 79 0.76 -0.04 - - - 
Year 3 cost 79 0.57 0.07 - - - 
Ln primary care cost 79 0.96 -0.01 76 0.12 0.36 
Secondary care cost 79 0.62 -0.06 - - - 
Wheeze cost 79 0.95 0.01 - - - 
Cough cost 79 0.98 -0.003 - - - 
UTRI cost 79 0.42 -0.09 - - - 
LRTI cost 79 0.28 0.12 - - - 
Bronchiolitis cost 79 0.55 -0.07 - - - 
Ln Overall Resp 
cost 
79 0.35 -0.10 76 -0.05 0.74 
Food allergy cost 79 0.86 -0.02 - - - 
Eczema cost 79 0.12 0.18 - - - 
β (Beta coefficient),  (Spearmans correlation coefficient), URTI (Upper respiratory tract 
infection, LRTI (Lower respiratory tract infection). 
1Adjusted for treatment group, mother’s age, mother’s age on leaving education and 
gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle Eastern, 
Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or 
caesarean) as potential cofactors.  
 
 
 
Table 10. Childhood 25(OH)D levels and healthcare utilisation in the first three years 
of life. 
Outcome n p β or  n Adjusted
1 β p 
Ln total healthcare 65 0.52 -0.08 63 -0.07 0.68 
Ln all visit cost 65 0.49 -0.09 63 -0.08 0.66 
Ln all prescription cost 65 0.88 0.02 63 -0.007 0.97 
Ln year 1 cost 65 0.63 -0.06 63 -0.05 0.76 
Year 2 cost 65 0.52 -0.08 - - - 
Year 3 cost 65 0.24 -0.15 - - - 
Ln primary care cost 65 0.86 0.02 63 0.12 0.93 
Secondary care cost 65 0.70 -0.05 - - - 
Wheeze cost 65 0.72 0.05 - - - 
Cough cost 65 0.56 0.07 - - - 
UTRI cost 65 0.21 -0.16 - - - 
LRTI cost 65 0.50 -0.09 - - - 
Bronchiolitis cost 65 0.94 -0.01 - - - 
Ln overall Resp cost 65 0.11 -0.20 63 -0.14 0.45 
Food allergy cost 65 - - - - - 
Eczema cost 65 0.86 0.02 - - - 
β (Beta coefficient),  (Spearmans correlation coefficient), URTI (Upper respiratory tract 
infection, LRTI (Lower respiratory tract infection). 
1Adjusted for treatment group, mother’s age, mother’s age on leaving education and 
gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle Eastern, 
Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or 
caesarean) as potential cofactors. 
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Discussion 
We evaluated whether two specific dosing regimens of prenatal vitamin D supplementation 
could reduce health care utilisation in the first three years of life. We found no consistent 
evidence for a treatment effect on overall or disease-specific unscheduled healthcare 
utilisation in the first three years, although it should be noted that neither of the intervention 
regimens resulted in adequate vitamin D levels in mothers or cord blood, judged by current 
international vitamin D recommendations [36, 37]. We found no evidence that prenatal 
vitamin D status is related to healthcare utilisation, however one might argue that the very 
small number of subjects with adequate vitamin D status limited the power of this analysis. 
These data contrast with recent findings that higher dose vitamin D during pregnancy and 
infancy can reduce upper respiratory tract infections in infancy [38]. Our new findings 
suggest that prenatal maternal vitamin D levels may be less important than postnatal infant 
vitamin D levels for determining infant health outcomes, at least within the 
insufficient/deficient range. Strength is lent to this conclusion when the healthcare utilisation 
data are contextualised within the other clinical data obtained from this trial in which 
supplementation did not influence odds of respiratory or allergic symptoms, or measures of 
lung function/inflammation and immune development [14]. Our data failed to show any 
significant difference between the total healthcare costs of children from control vs. 
supplemented mothers, with an adjusted mean difference of £1.17 (p=0.52). Considering the 
cost of the pharmaceuticals required for intervention (as per 2011); of £50.18 for daily 
supplement and £10.59 for bolus dosing, this suggests that supplementation solely for this 
purpose would not be cost-effective. [39] 
 
Studies in other populations, usually with higher prenatal vitamin D status than ours, have 
found an inverse relationship between cord blood 25(OH) vitamin D level and child health 
outcomes [4]. However intervention trials have not yet shown this relationship to be a causal 
one. The findings from our trial, the first prenatal vitamin D intervention trial to report child 
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health outcomes, suggest that either the dosing regimen used in this study was inadequate, 
or that the relationship between cord blood 25(OH) vitamin D and child health seen in 
observational studies may be related to hidden confounders. It is important to consider the 
generalisability and limitations of these conclusions. First the effect (or lack of effect) of the 
specific timing and dose of vitamin D used in our study cannot be generalised to other 
dosing and timing schedules. While our interventions did result in at least 50% higher cord 
blood 25(OH)D concentrations compared with no treatment, cord blood levels were 
significantly lower in our intervention groups [daily dose 26nmol/l (IQR 17-45); bolus dose 
25nmol/l (IQR 18-34)] than in studies that have found protective associations between 
higher early life 25(OH)D levels on wheezing or respiratory tract infections in early childhood 
(Camargo 44nmol/L (IQR 29-78) [4]; Morales 74nmol/L (IQR 56-93) [6]; Belderbos 82nmol/L 
(SE 3.5) [40]). The recent New Zealand intervention trial showing reduced acute respiratory 
tract infections between 6 and 18 months of life in offspring of Vitamin D supplemented 
mothers found a higher vitamin D dose was necessary for clinical efficacy, and infants were 
supplemented in addition to mothers [38]. Maternal serum 25(OH) vitamin D levels in that 
trial were higher at randomization, and rose to a higher level in the supplemented groups - 
from ~60 to ~100 nmol/L; compared to ~26 to ~40 nmol/L in our trial. . At the time of the 
initial trial the national UK recommendation for supplementation during pregnancy was 
400IU (10mcg) once daily. This continues to be recommended and is integrated into the 
‘Healthy Start’ multivitamin tablets. However, guidance from the National Institute for Clinical 
Excellence and Royal College of Obstetricians and Gynaecologists in the UK now 
acknowledge this as a minimum dose for all pregnant or breastfeeding women and that 
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higher dosing should be considered in those at high risk of vitamin D deficiency[41, 42]. 
More recent guidance from the Institute of Medicine estimates 400IU as average daily 
requirement in adults in the US and Canada but recommends that supplementation of 600IU 
would ensure most people achieved sufficiency in their target population [37, 43] In a review 
by Holick et al. in 2011 greater intervention was suggested with baseline dosing of 600IU, 
increasing to 1500-2000IU in those at risk of deficiency. In addition, higher thresholds of 
25(OH) Vitamin D were recommended for deficiency (<50nmol/l) and insufficiency (52.5-
72.5nmol/l) [36]. Despite our daily dosing being above the baseline recommendation and 
showing increase in maternal and cord blood 25(OH) Vitamin D, by these definitions only 
around 30% of the women in the trial achieved sufficiency, therefore our data likely reflect 
outcomes looking at the shift from deficient to insufficient and not full replenishment. With 
the endorsement of not only different dosing regimes but different safe upper limits (4,000 
IU/day (IOM) versus upto 10,000IU/day (Holick et al.), there remains an important question 
whether prenatal vitamin D supplementation at doses which reliably achieve sufficiency in 
the target population, can improve healthcare outcomes for young children. The relationship 
between prenatal vitamin D status and child health outcomes may not be linear. Given that 
some observational studies suggest adverse child respiratory health outcomes are 
associated with very high maternal vitamin D level during pregnancy, empiric data are 
needed before high dose prenatal vitamin D supplementation can be routinely 
recommended[44]. 
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A limitation of our findings is that healthcare utilization may be too crude, with large health 
effects required to influence total healthcare utilisation. However, the national framework for 
health provision in the UK provides a powerful resource of objective information, the merit of 
which has been validated in a systematic review [45, 46]. When prevalence is based on a 
combination of diagnosis and prescribing patterns, as we have done, the reliability of this 
resource further increases [47]. A further limitation of the study is its small size and  wide 
confidence intervals, so that a small effect of prenatal vitamin D on child healthcare 
utilization in the first 3 years cannot be confidently excluded. However the data were 
negative when evaluated in different ways, in both adjusted and unadjusted analyses. 
Overall the data suggest that a clinically meaningful relationship between this regime of 
vitamin D supplementation in pregnancy in a deficient population, or these levels of vitamin 
D in cord-blood or at three years of age, and healthcare utilization is unlikely.   
 
Other limitations of this study include the risk of selection bias with follow up rate of only 
55% of those randomised. Analyses with imputation for missing data were not undertaken 
due to the relatively small sample size. However, the characteristics of those included in 
analysis were similar to those that were excluded. Adjusted analyses were consistent with 
unadjusted analyses suggesting a low probability that confounding factors have altered the 
findings of this trial.   This was a diverse ethnic group. Variation in healthcare use has been 
reported between ethnic minorities in the UK, with lower levels of asthma diagnosis and 
treatment in people from the Indian subcontinent [48, 49] but higher consultation frequency 
[50, 51]. However, multivariate analysis of our data showed that although maternal ethnicity 
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correlated with 25(OH) vitamin D level there was no relationship between maternal ethnicity 
and our measures of healthcare utilization in this trial. 
 
In conclusion we have found no evidence that supplementation of a vitamin D deficient, 
urban mixed race population with either a single oral bolus dose of 200,000 IU 
cholecalciferol at 27 weeks or 800 IU ergocalciferol daily from 27 weeks until delivery had 
any effect on child healthcare utilization in the first 3 years of life. Moreover we found no 
evidence of a relationship between cord blood 25(OH) vitamin D level and healthcare 
utilization in this population. Although our confidence in the findings is limited by the small 
sample size, these data suggest that if prenatal vitamin D is used to promote improved child 
health outcome, then a postnatal component to treatment, and/or or higher doses may be 
needed. 
 
A recent systematic review of prenatal vitamin D supplementation found heterogeneous 
study designs and inconsistent findings [52]. Outcomes of a subsequent intervention trial 
suggest that higher dose vitamin D, and possibly combined mother/infant supplementation 
may be needed for positive health effects on the child [38]. In that context further data are 
awaited from two larger randomised controlled trials, VDARRT [53] and ABCVitaminD [54], 
to establish whether higher dose daily prenatal vitamin D supplementation will impact on 
child health outcomes. 
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